Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo to dissolve subsidiaries with Sanofi-Aventis
The impact of this dissolution on the earnings of Daiichi Sankyo of the fiscal year ending March 2009 will be negligible, the company said. Daiichi Sankyo and Sanofi-Aventis
The impact of this dissolution on the earnings of Daiichi Sankyo of the fiscal year ending March 2009 will be negligible, the company said. Daiichi Sankyo and Sanofi-Aventis
The special access program (SAP) provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable or are
With this agreement, Oridion becomes Kaiser’s sole supplier for Oridion’s consumable products, thus providing savings for the entire Kaiser system of hospitals and outpatient facilities. The Kaiser network
Under the research collaboration, InteRNA will apply its unique lentiviral-based miRNA overexpression library in multi-parametric, high-throughput screening assays to identify the biological role of individual miRNAs and novel
Eprotirome induced a statistically significant and clinically relevant lowering of serum low-density lipoprotein (LDL)-cholesterol, triglycerides and lipoprotein(a) and was safe and well tolerated. Data show that eprotirome in
One milestone was achieved for the start of lead optimization for a specific target. This means that for the third time within this collaboration, a program has been
This second milestone related to the start of the Fentanyl Taifun Phase III program should be followed within the next quarter by the enrollment of the first patients
The agreement provides for an upfront payment, equity participation and royalties on sales of licensed products, subject to certain minimum amounts. The license does not cover Xenomics current
ANA773 is the company’s investigational oral TLR7 agonist prodrug. In part B of the study, patients in the first cohort will receive 800mg of ANA773 every other day
Mr Still has been serving in the capacity of president and COO for the company since earlier 2008. Prior to Accumetrics, Mr Still was executive vice president and